Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
4
80%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

completed240%
unknown120%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

NCT00782093
unknownphase_2

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00278187
completedphase_2

A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

NCT00401570
terminatedphase_2

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

NCT00516841
terminatedphase_2

A Study of Volociximab in Metastatic Melanoma

NCT00369395

Clinical Trials (5)

Showing 5 of 5 trials
NCT00782093Phase 1

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

Completed
NCT00278187Phase 2

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Unknown
NCT00401570Phase 2

A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

Completed
NCT00516841Phase 2

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Terminated
NCT00369395Phase 2

A Study of Volociximab in Metastatic Melanoma

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5